Clinical Trial Update: Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) [Phase 3]

View source ↗

Summary

Phase 3 trial of avelumab in third-line gastric cancer has completed; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line | Phase 3 | Status: COMPLETED | Results posted: 2018-10-15